Skip to content

Ocular Hypotensive effects of topical versus sublingual brimonidine: a cross-over study

Ocular Hypotensive effects of topical versus sublingual brimonidine: a cross-over study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240217061030N2
Enrollment
30
Registered
2024-11-14
Start date
2024-11-13
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma. Primary open-angle glaucoma

Interventions

Intervention 1: Intervention group 1: For group 1, brimonidine is administered sublingually every 8 hours for 4 weeks, and the next visit time (4 weeks later
that is, 1 week more than the drug washout) is determined. In the second visit, the initial intraocular pressure is measured and recorded, and a water drinking test is performed for the patient. Then,

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with ocular hypertension (ocular HTN) (intraocular pressure above 21 mm Hg) Patients with early stages of early open-angle glaucoma (early POAG)

Exclusion criteria

Exclusion criteria: Patients with bradycardia Patients with a history of heart disease Patients with hypotension

Design outcomes

Primary

MeasureTime frame
Intraocular pressure. Timepoint: 4, 8 and 12 weeks. Method of measurement: Goldman Tonometry.

Secondary

MeasureTime frame
Systemic complications, local complications. Timepoint: 4, 8 and 12 weeks. Method of measurement: questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Mohammadzadeh

Shahid Beheshti University of Medical Sciences

Amir.mohammadzadeh74@gmail.com+98 21 7762 6550

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026